A retrospective, observational, cohort assessing the weight gain in treatment with abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravirin patients with treatment-naïve HIV-1 infection
Latest Information Update: 15 Dec 2021
At a glance
- Drugs Abacavir/dolutegravir/lamivudine (Primary) ; Bictegravir/emtricitabine/tenofovir alafenamide (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions
- 01 Jan 2022 Results published in the AIDS
- 15 Dec 2021 New trial record